Nanobodies News and Research

RSS

SARS-CoV-2 nanobody that binds to the receptor-binding domain could prevent COVID-19 in animals

A new study assessed the potential of a nanobody – directly prepared by binding to SARS-CoV-2 spike receptor-binding domain protein, in the treatment of COVID-19.

22 Mar 2022

Covalent protein nanobodies for neutralizing SARS-CoV-2 and its variants

Researchers developed covalent nanobodies to neutralize severe acute respiratory syndrome coronavirus-2 and its variants.

18 Mar 2022

Protection against SARS-CoV-2 Omicron variant by hetero-bivalent nanobodies

A new study investigated the broad-spectrum protection provided by hetero-bivalent nanobodies against SARS-CoV-2 variants of concern, such as Omicron.

14 Mar 2022

Identification of a rapid test for SARS-CoV-2 neutralization via antibodies and nanobodies

Researchers presented a technique called rapid in vitro inhibition assay (RIVIA), whereby potential SARS-CoV-2 antibody and nanobody candidates can be rapidly screened.

8 Mar 2022

Molecular characteristics of SARS-CoV-2 variants enabling antibody escape

A new review paper published in PLoS Pathogens discusses the new variants and the structural mechanism underlying antibody-mediated neutralization as well as mutational antibody escape.

21 Feb 2022

Inhalable antibody fragments offer broad protection from SARS-CoV-2 variants

A new study describes a potential new approach to treating COVID-19 in the form of single-chain fragment variable (scFv) antibodies.

20 Feb 2022

Alpaca-derived antibody fragment disrupts interaction between SARS-CoV-2 spike protein and human ACE2

Researchers have been investigating the potential for using nanobodies – special immune particles from llamas and alpacas – against the disease.

24 Jan 2022

Study finds pan-sarbecovirus nanobodies can enhance development of super-immunity

A new study found that applying pan-sarbecovirus nanobodies shows a strong affinity toward all sarbecovirus clades and neutralized SARS-CoV-2 receptor binding domains

4 Jan 2022

Scientists identify a panel of nanobodies with good neutralizing efficacy against SARS-CoV-2 variants of concern

A team of scientists from Canada has recently characterized a panel of nanobodies against the spike protein of SARS-CoV-2.

22 Dec 2021

Driving up immunity at tumor site may help enhance immunotherapy treatments

Driving up the immune response at the site of a cancer tumor with nanotechnology may help enhance immunotherapy treatments in advanced stages of the disease, new research in mice suggests.

14 Dec 2021

SARS-CoV-2 Omicron variant may bind with ACE2 receptor more efficiently

A new study discusses the effect of the Omicron variant’s mutations on its binding efficiency to the ACE2 receptor.

9 Dec 2021

Broad neutralization capability of potent nanobody against SARS-CoV-2 variants

A new study has described the molecular basis of the neutralization potency and breadth of nanobodies.

16 Nov 2021

New type of COVID vaccine potentially easier to produce and does not need refrigeration

Currently available COVID vaccines require cold storage and sophisticated manufacturing capacity, which makes it difficult to produce and distribute them widely, especially in less developed countries.

6 Nov 2021

SARS-CoV-2 neutralizing antibodies discovered in a 20-year-old human antibody library

In an article published in the open-access journal Advance Engineering, a multinational team of researchers reported the selection and characterization of 3 potent SARS-CoV-2 antibodies - S-E6, S-B8, and S-D4 - from a pre-COVID-19 human combinatorial antibody library that was established 20 years ago.

3 Nov 2021

SARS-CoV-2 variants neutralized by camel nanobodies

Researchers from the US recently isolated two VHH nanobodies - 7A3 and 8A2 - from dromedary camels (Camelus dromedaries) using phage display. These nanobodies were found to have a high affinity for the spike RBD and broad neutralization abilities against SARS-CoV-2 and its variants.

2 Nov 2021

Identification of novel nanobodies to specifically target SARS-CoV-2 replication protein

Researchers have recently identified two nanobodies that show specific binding against a SARS-CoV-2 replication protein.

1 Nov 2021

Panel of broadly neutralizing SARS-CoV-2 nanobodies for immune assay application

In this study, a team of researchers from Japanese institutions provide a panel of broadly neutralizing nanobodies that detect four VOCs.

28 Oct 2021

A high-throughput pipeline for identifying nanobodies that target and neutralize SARS-CoV-2

Researchers in the United States have developed a cost-effective, high-throughput pipeline for identifying effective nanobodies that target and neutralize severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) – the agent that causes coronavirus disease 2019 (COVID-19).

26 Oct 2021

The neutralization potential of nanobodies against SARS-CoV-2

A recent review describes the role of nanobodies as a new class of recombinant antibodies that are used in the treatment of COVID-19.

20 Oct 2021

Unique tiny Ilamas antibodies could be used for treatment of COVID-19

A unique type of tiny antibody produced by llamas could provide a new frontline treatment against Covid-19 that can be taken by patients as a simple nasal spray.

22 Sep 2021